Quell Therapeutics is a London-based cell therapy company on a mission to develop engineered T-regulatory (Treg) cell therapies for a range of solid organ transplant and autoimmune conditions. Founded in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation, and autoimmune diseases, Quell Therapeutics is poised to become a leading player in the cell therapy market.
Vision and Mission
Quell Therapeutics has a clear and ambitious vision: to become a leading engineered Treg cell therapy company. To achieve this vision, the company is focused on developing next-generation Treg cell therapies that can treat a range of solid organ transplant and autoimmune conditions. Quell Therapeutics believes that its innovative approach to cell therapy will revolutionize the way these conditions are treated and provide patients with new hope for improved health and quality of life.
Expertise and Partnership
Quell Therapeutics is founded on the expertise of six leading experts in the Treg field, cell engineering, solid organ transplantation, and autoimmune diseases. Giovanna Lombardi, Alberto Sanchez-Fueyo, Hans Stauss, Emma Morris, Marc Martinez-Llordella, and Elmar Jaeckel bring decades of experience and knowledge to Quell Therapeutics. This expertise is complemented by a partnership with Syncona, a leading healthcare investment firm, which provides the financial backing and strategic support necessary to bring Quell’s vision to life.
Cutting-Edge Technology
At the heart of Quell Therapeutics’ vision is its cutting-edge technology. The company is focused on developing engineered Treg cell therapies that can be tailored to treat specific solid organ transplant and autoimmune conditions. By engineering Treg cells, Quell Therapeutics aims to overcome the limitations of current cell therapies and provide patients with more effective and targeted treatments. The company’s innovative approach to cell therapy has the potential to transform the lives of millions of people suffering from these conditions.
Clinical Trials
Quell Therapeutics is currently conducting preclinical trials to evaluate the safety and efficacy of its engineered Treg cell therapies. The company’s goal is to advance its therapies to clinical trials in the near future. Quell Therapeutics is committed to working with patients, clinicians, and regulators to ensure that its therapies meet the highest standards of safety and efficacy. The company’s clinical trials will be a critical milestone in its journey to become a leading player in the cell therapy market.
Conclusion
Quell Therapeutics is a cell therapy company with a clear vision, ambitious goals, and cutting-edge technology. Its innovative approach to cell therapy has the potential to revolutionize the way solid organ transplant and autoimmune conditions are treated. With a team of leading experts and the financial backing of Syncona, Quell Therapeutics is well-positioned to achieve its vision and become a major player in the cell therapy market.
Website: https://www.quell-tx.com/
Twitter: https://twitter.com/quell_tx
LinkedIn: https://www.linkedin.com/company/quell-therapeutics
Facebook: https://www.facebook.com/QuellTherapeutics/
Want to supercharge your brand’s visibility within the UK tech industry? Reach startup founders, investors, and C-level executives with sponsored articles on UKT.news. Connect with us and discover how our advertising solutions can propel your brand to new heights. Explore our Sponsored Articles & Partnerships Program here.
